$SPDR S&P 500 ETF Trust(SPY)$

$SPDR S&P 500 ETF Trust(SPY)$ $iShares Biotechnology ETF(IBB)$ AI disruption in biotech is already happening, and $Eli Lilly(LLY)$ looks like the clear leader right now. They're using deep structural AI to accelerate drug development through the partnership with $Alphabet(GOOG)$ Isomorphic Labs and Genetic Leap. The company is already in high-margin commercial markets, has a bulletproof balance sheet, and the AtaiBeckley acquisition gives them a lead in the psychedelic drug space, which I think could be a blockbuster. I've been waiting for a decent pullback from the highs, and picked up some shares at a discount.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":593241751393792,"tweetId":"593241751393792","gmtCreate":1785801450000,"gmtModify":1785851013674,"author":{"id":10000000000010990,"idStr":"10000000000010990","authorId":10000000000010990,"authorIdStr":"10000000000010990","name":"Merle Ted","avatar":"https://static.tigerbbs.com/d0681550b13e51a8ffa4c08327616955","vip":8,"userType":8,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":55,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","html":"<html><head></head><body><p><a href=\"https://ttm.financial/S/SPY\">$SPDR S&amp;P 500 ETF Trust(SPY)$&nbsp;</a><a href=\"https://ttm.financial/S/IBB\">$iShares Biotechnology ETF(IBB)$&nbsp;</a>AI disruption in biotech is already happening, and <a href=\"https://ttm.financial/S/LLY\">$Eli Lilly(LLY)$&nbsp;</a> looks like the clear leader right now. They're using deep structural AI to accelerate drug development through the partnership with <a href=\"https://ttm.financial/S/GOOG\">$Alphabet(GOOG)$&nbsp;</a> Isomorphic Labs and Genetic Leap. The company is already in high-margin commercial markets, has a bulletproof balance sheet, and the AtaiBeckley acquisition gives them a lead in the psychedelic drug space, which I think could be a blockbuster. I've been waiting for a decent pullback from the highs, and picked up some shares at a discount.</p></body></html>","htmlText":"<html><head></head><body><p><a href=\"https://ttm.financial/S/SPY\">$SPDR S&amp;P 500 ETF Trust(SPY)$&nbsp;</a><a href=\"https://ttm.financial/S/IBB\">$iShares Biotechnology ETF(IBB)$&nbsp;</a>AI disruption in biotech is already happening, and <a href=\"https://ttm.financial/S/LLY\">$Eli Lilly(LLY)$&nbsp;</a> looks like the clear leader right now. They're using deep structural AI to accelerate drug development through the partnership with <a href=\"https://ttm.financial/S/GOOG\">$Alphabet(GOOG)$&nbsp;</a> Isomorphic Labs and Genetic Leap. The company is already in high-margin commercial markets, has a bulletproof balance sheet, and the AtaiBeckley acquisition gives them a lead in the psychedelic drug space, which I think could be a blockbuster. I've been waiting for a decent pullback from the highs, and picked up some shares at a discount.</p></body></html>","text":"$SPDR S&P 500 ETF Trust(SPY)$ $iShares Biotechnology ETF(IBB)$ AI disruption in biotech is already happening, and $Eli Lilly(LLY)$ looks like the clear leader right now. They're using deep structural AI to accelerate drug development through the partnership with $Alphabet(GOOG)$ Isomorphic Labs and Genetic Leap. The company is already in high-margin commercial markets, has a bulletproof balance sheet, and the AtaiBeckley acquisition gives them a lead in the psychedelic drug space, which I think could be a blockbuster. I've been waiting for a decent pullback from the highs, and picked up some shares at a discount.","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/593241751393792","repostId":0,"isVote":1,"tweetType":1,"viewCount":201,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["IBB","LLY","SPY","GOOG"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":526,"optionInvolvedFlag":false,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/593241751393792"}